Alto Neuroscience, Stock Performance
| ANRO Stock | 4.28 0.05 1.15% |
The firm shows a Beta (market volatility) of 3.94, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Alto Neuroscience, will likely underperform. At this point, Alto Neuroscience, has a negative expected return of -0.82%. Please make sure to confirm Alto Neuroscience,'s treynor ratio, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Alto Neuroscience, performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Alto Neuroscience, has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Actual Historical Performance (%)
One Day Return (1.15) | Five Day Return 3.88 | Year To Date Return (79.32) | Ten Year Return (79.32) | All Time Return (79.32) |
1 | Acquisition by Savitz Adam of 10681 shares of Alto Neuroscience, at 12.53 subject to Rule 16b-3 | 09/09/2024 |
2 | Alto Neurosciences Market Cap Drops To US358m Leaving Insiders With Losses | 09/25/2024 |
3 | Lost Money on Alto Neuroscience, Inc. You May Have Been Affected by Fraud- Contact Levi Korsinsky | 10/28/2024 |
4 | Did Alto Neuroscience, Inc. Mislead Investors Shareholder Rights Advocates at Levi Korsinsky Investigate- ANRO | 11/05/2024 |
5 | Alto Neuroscience Inc Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Reach Out To The Schall Law Firm | 11/06/2024 |
6 | The Schall Law Firm Invites Stockholders To Take Part In An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud | 11/12/2024 |
7 | Stifel Nicolaus Issues Pessimistic Forecast for Alto Neuroscience Stock Price | 11/13/2024 |
8 | RA Capital Management Reduces Stake in Alto Neuroscience Inc | 11/15/2024 |
9 | The Schall Law Firm Wants Shareholders To Join An Inquiry Into Alto Neuroscience, Inc. For Fraud | 11/18/2024 |
10 | Board of Trustees of The Leland Stanford Junior University Sells 264,273 Shares of Alto Neuroscience, Inc. | 11/21/2024 |
11 | Alto Neuroscience Inc Is Being Investigated For Violating Securities Laws And Affected Investors Are Encouraged To Reach Out To The Schall Law Firm | 11/27/2024 |
| Begin Period Cash Flow | 48.3 M |
Alto |
Alto Neuroscience, Relative Risk vs. Return Landscape
If you would invest 1,281 in Alto Neuroscience, on August 30, 2024 and sell it today you would lose (853.00) from holding Alto Neuroscience, or give up 66.59% of portfolio value over 90 days. Alto Neuroscience, is currently does not generate positive expected returns and assumes 9.9596% risk (volatility on return distribution) over the 90 days horizon. In different words, 88% of stocks are less volatile than Alto, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Alto Neuroscience, Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Alto Neuroscience,'s investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Alto Neuroscience,, and traders can use it to determine the average amount a Alto Neuroscience,'s price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0822
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ANRO |
Estimated Market Risk
| 9.96 actual daily | 88 88% of assets are less volatile |
Expected Return
| -0.82 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.08 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Alto Neuroscience, is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Alto Neuroscience, by adding Alto Neuroscience, to a well-diversified portfolio.
Alto Neuroscience, Fundamentals Growth
Alto Stock prices reflect investors' perceptions of the future prospects and financial health of Alto Neuroscience,, and Alto Neuroscience, fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Alto Stock performance.
| Current Valuation | 184.12 M | ||||
| Shares Outstanding | 26.96 M | ||||
| Price To Book | 2.04 X | ||||
| EBITDA | (34.56 M) | ||||
| Net Income | (36.3 M) | ||||
| Total Debt | 151.46 M | ||||
| Book Value Per Share | 6.67 X | ||||
| Cash Flow From Operations | (33.45 M) | ||||
| Earnings Per Share | (1.85) X | ||||
| Market Capitalization | 367.18 M | ||||
| Total Asset | 86.63 M | ||||
| Retained Earnings | (76.97 M) | ||||
| Working Capital | 79.78 M | ||||
About Alto Neuroscience, Performance
By examining Alto Neuroscience,'s fundamental ratios, stakeholders can obtain critical insights into Alto Neuroscience,'s financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Alto Neuroscience, is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.42) | (0.44) | |
| Return On Capital Employed | (0.47) | (0.49) | |
| Return On Assets | (0.42) | (0.44) | |
| Return On Equity | 0.51 | 0.72 |
Things to note about Alto Neuroscience, performance evaluation
Checking the ongoing alerts about Alto Neuroscience, for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Alto Neuroscience, help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Alto Neuroscience, generated a negative expected return over the last 90 days | |
| Alto Neuroscience, has high historical volatility and very poor performance | |
| Alto Neuroscience, has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (36.3 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Alto Neuroscience, generates negative cash flow from operations | |
| Alto Neuroscience, has a frail financial position based on the latest SEC disclosures | |
| Over 75.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from accesswire.com: Alto Neuroscience Inc Is Being Investigated For Violating Securities Laws And Affected Investors Are Encouraged To Reach Out To The Schall Law Firm |
- Analyzing Alto Neuroscience,'s financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Alto Neuroscience,'s stock is overvalued or undervalued compared to its peers.
- Examining Alto Neuroscience,'s industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Alto Neuroscience,'s management team can have a significant impact on its success or failure. Reviewing the track record and experience of Alto Neuroscience,'s management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Alto Neuroscience,'s stock. These opinions can provide insight into Alto Neuroscience,'s potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alto Neuroscience,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Alto Stock, please use our How to Invest in Alto Neuroscience, guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alto Neuroscience,. If investors know Alto will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alto Neuroscience, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.85) |
The market value of Alto Neuroscience, is measured differently than its book value, which is the value of Alto that is recorded on the company's balance sheet. Investors also form their own opinion of Alto Neuroscience,'s value that differs from its market value or its book value, called intrinsic value, which is Alto Neuroscience,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alto Neuroscience,'s market value can be influenced by many factors that don't directly affect Alto Neuroscience,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alto Neuroscience,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Alto Neuroscience, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alto Neuroscience,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.